Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma

Cancer Biomarkers

Volumn 5, Issue 1, 2009, Pages 1-8

  Mohammadizadeh, Fereshteh ^a   Ghasemibasir, Hamidreza ^a   Rajabi, Parvin ^a   Naimi, Azar ^a   Eftekhari, Amin ^a   Mesbah, Alireza ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; E cadherin; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; UVOMORULIN;

ARTICLE; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAN; LYMPH NODE METASTASIS; MOLECULAR DYNAMICS; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; PARAFFIN EMBEDDING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61449163133     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0551     Document Type: Article

References (26)

1. K. Strumane, A. Bonnomet, C. Stove, R. Vandenbroucke, B. Nawrocki-Raby, E. Bruyneel et al., E-Cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion, Cancer Res 66(20) (15 Oct. 2006), 10007-10015.
2. A. Eger, K. Aigner, S. Sonderegger, B. Dampier, S. Oehler, M. Schreiber et al., DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells, Oncogene 24(14) (31 Mar. 2005), 2375-2385.
3. C.G. Kleer, K.L. van Golen, T. Braun and S.D. Merajver, Persistent E-cadherin expression in inflammatory breast cancer, Mod Pathol 14(5) (May 2001), 458-464.
4. R. Kemler, From cadherins to catenins: Cytoplasmic protein interactions and regulation of cell adhesion, Trends Genet 9(9) (Sep. 1993), 317-321.
5. I.K. Bukholm, J.M. Nesland, R. Karesen, U. Jacobsen and A.L. Borresen-Dale, Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas, Virchows Arch 431 5) (Nov. 1997), 317-321.
6. U. Jeschke, I. Mylonas, C. Kuhn, N. Shabani, C. Kunert-Keil, C. Schindlbeck et al., Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence, Anticancer Res 27(4A) (Jul-Aug. 2007), 1969-1974.
7. U. Jeschke, I. Mylonas, N. Shabani, C. Kunert-Keil, C. Schindlbeck, B. Gerber and K. Friese, Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: Immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis, Anticancer Res 25(3A) (May-Jun. 2005), 1615-1622.
8. A.K. Perl, P. Wilgenbus, U. Dahl, H. Semb and G. Christofori, A causal role for E-cadherin in the transition from adenoma to carcinoma, Nature 392(6672) (12 Mar. 1998), 190-193.
9. K.S. Asgeirsson, J.G. Jonasson, L. Tryggvadottir, K. Olafsdottir, J.R. Sigurgeirsdottir, S. Ingvarsson et al., Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance, Eur J Cancer 36(9) (Jun. 2000), 1098-1106.
10. C. Charpin, S. Garcia, C. Bouvier, B. Devictor, L. Andrac, R. Choux et al., E-cadherin quantitative immunocytochemical assays in breast carcinomas, J Pathol 181(3) (Mar. 1997), 294-300.
11. E.M. Howard, S.K. Lau, R.H. Lyles, G.G. Birdsong, J.N. Umbreit and R. Kochhar, Expression of e-cadherin in high-risk breast cancer, J Cancer Res Clin Oncol 131(1) (Jan. 2005), 14-18.
12. E.A. Rakha, D. Abd El Rehim, S.E. Pinder, S.A. Lewis and I.O. Ellis, E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance, Histopathology 46(6) (April. 2005), 685-693.
13. X.C. Hu, I.H. Wong and L.W. Chow, Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: Clinical implications, Oncol Rep 10(6) (Nov-Dec. 2003), 1811-1815.
14. C.G. Colpaert, P.B. Vermeulen, I. Benoy, A. Soubry, F. van Roy, P. van Beest et al., Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression, Br J Cancer 88(5) (10 Mar. 2003), 718-725.
15. V.F. Chekhun, N.Y. Lukyanova, O. Kovalchuk, V.P. Tryndyak and I.P. Pogribny, Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets, Mol Cancer Ther 6(3) (Mar. 2007), 1089-1098.
16. M. Viswanathan, S.P. Solomon, N. Tsuchida, G.S. Selvam and G. Shanmugam, Methylation of E-cadherin and hMLH1 genes in Indian sporadic breast carcinomas, Indian J Exp Biol 44(2) (Feb. 2006), 115-119.
17. K. Fabianowska-Majewska, R. Kordek and B. Krawczyk, Studies on the methylation status of CpG sequences located in promoters of selected tumour suppressor genes in breast cancer cells, Nucleosides Nucleotides Nucleic Acids 25(9-11) (2006), 1025-1028.
18. C.J. Fabian, B.F. Kimler, R.M. Elledge, W.E. Grizzle, S.W. Beenken, J.H. Ward et al., Models for early chemoprevention trials in breast cancer, Hemat Oncol Clin North Am 12(5) (Oct. 1998), 993-1017.
19. J. Rosai, Rosai and Ackerman's surgical pathology, 9th ed., Edinburgh: Mosby (2004), 1787-1827.
20. S.W. Beenken, W.E. Grizzle, D.R. Crowe, M.G. Conner, H.L. Weiss, M.T. Sellers et al., Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53, Ann Sur 233(5) (May 2001), 630-638.
21. E.M. Howard, S.K. Lau, R.H. Lyles, G.G. Birdsong, T.S. Tadros, J.N. Umbreit et al., Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population, Int J Clin Oncol 9(3) (June 2004), 154-160.
22. C.E. Gillett, D.W. Miles, K. Ryder, D. Skilton, R.D. Liebman, R.J. Springall et al., Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast, J Pathol 193(4) (Apr. 2001), 433-441.
23. B. D'souza and J. Taylor-Papadimitriou, Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene, Proc Natl Acad Sci USA 91(15) (19 Jul. 1994), 7202-7206.
24. C. Charpin, S. Garcia, P. Bonnier, F. Martini, L. Andrac, R. Choux et al., Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival, Am J Clin Pathol 109(4) (Apr. 1998), 431-438.
25. S. Sjogren, M. Inganas, A. Lindgren, L. Holmberg and J.L. Bergh, Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers, J Clin Oncol 16(2) (Feb. 1998), 462-469.
26. H. Tsuda, C. Sakamaki, S. Tsugane, T. Fukutomi, S. Hirohashi et al., A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases, Breast Cancer Res Treat 48(1) (Mar. 1998), 21-32.